Home   Jobs   Conferences   Fellowships   Books   Buyer's Guide   Feature Page



Advertisement
Advertisement



17 July 2014: Leica Microsystems announces the Leica Application Suite Advanced Fluorescence (LAS AF), the software platform for advanced life science research in widefield and confocal microscopy, in its 4.0 version. With LAS AF, researchers can now perform 2D image analysis on multi-channel experiments and fully control the environmental conditions of an experiment. In addition, users of widefield systems can now connect to the acquisition station remotely anywhere at any time.



A workflow guides users step by step through the 2D image analysis from applying filters, thresholding, and binary image processing, to measurements and classification. Results are obtained easily, quickly, and reproducibly even with multi-dimensional data sets. Each analysis step offers a set of tools that researchers can choose according to the analysis requirements. The image viewer provides immediate feedback on the applied settings.

Please click here for more information.






30 June 2014: Milestone introduces SealSAFE, a system for eliminating formalin exposure and standardizing fixative volumes during specimen management and transport.

SealSAFE enables Surgical and Laboratory professionals to safely manage and tranfer patient specimens from the OR to Pathology using laboratory grade vacuum bags. Specimen bags are placed into a sealing chamber, automatically weighed, then a preselected ratio of fixative is added prior to vacuum completion. The fully vented unit extracts formalin fumes from the reagent drawer and sealing chamber, keeping users safe.

Benefits include reduced exposure to harmful fumes, lower fixative use through more efficient ratios, documentation of fixation start time, barcode identification of specimens, and cost reductions in waste disposal of archived case tissue.

  

Learn the complete SealSAFE story by calling 866-995-5300, emailing info@milestonemed.com or visiting www.milestonemed.com.







27 June 2014: Bio SB announces two new micro-polymer based detection systems for in vitro diagnostic use: PolyDetector, and PolyDetector Plus. Coupled with the Bio SB Biotin/Streptavidin based ImmunoDetector, Bio SB offers a complete portfolio of highly sensitive and cost effective IVD Immunohistochemistry detection systems for research and clinical use.

The Bio SB PolyDetector and PolyDetector Plus systems are non-biotin, micro-polymeric detection system that allows for the demonstration of antigens in formalin-fixed paraffin-embedded tissue, cryostat sections, blood smears, cytosmears, and cell preparations. The Bio SB PolyDetector & PolyDetector Plus detection systems were developed using proprietary tandem hyperlabelling micro-polymer technology used to directly label immunoglobulin fractions with enzymes. This technology ensures consistent and reproducible immunostaining for all types of nuclear, cytoplasmic and membranous antigens across different tissue types.

The increased sensitivity of the PolyDetector detection system allows for rapid staining procedures without compromising stain quality. Available in HRP and AP configurations, the PolyDetector is ideal for users wanting to implement multiplex IHC technologies into their laboratories. The PolyDetector Plus HRP kit differs from PolyDetector by incorporating a linking polymer and an HRP micro-polymer. This multiple component polymer delivers a highly sensitive and specific signal in a shorter time-frame for laboratories that need reduced turnaround time.

For more information, click here or email info@biosb.com.





23 June 2014: Leica Biosystems announces the release of several new features for its PathLead app. The mobile app, available for iPhone, iPad and Android, is an educational tool which includes an antibody citation index of now more than 100 antibodies, with continuous updates and an extensive IHC image library. Healthcare professionals in the field of surgical pathology and diagnostic immunohistochemistry can now access antibody lecture series and educational webinars available in concise 10 minute podcasts. All videos can be streamed or downloaded and viewed in both full portrait and landscape orientations. The information provided on PathLead does not endorse any specific vendor or product.

Please click here for more information.





23 June 2014: Photometrics announces its Evolve 512 Delta camera, which possesses the industry's fastest frame rates and highest sensitivity for a camera of its class. Equipped with a sensor running at 20MHz that captures images at 67.5 frames per second and read noise <1e- (using EM gain), the Evolve 512 Delta makes super-resolution imaging very productive and efficient. Other key features are >90% Quantum Efficiency and Quantitative Performance.

The camera was specifically designed for applications such as STORM, PALM and GSD. The camera is also suited for a range of other applications including SMF and Tracking, Live-cell Spinning Disk Confocal, SPIM, Intrinsic Imaging, FCS, TIRF, FRET and FRAP.

For more information, visit our website at www.photometrics.com/products/emccdcams/evolvedelta.php or email us at info@photometrics.com.





17 June 2014: To improve consistency and completeness in reporting results of cancer biomarker testing, the College of American Pathologists (CAP) has produced the Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens from Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction. This template was developed to respond to pathologist user feedback about timing of reporting and structural consistency of ancillary studies data elements in the CAP Cancer Protocols and to provide educational materials to help pathologists better understand emerging biomarkers. The development of these templates has been a collaborative effort between the CAP, AMP, ASCO, CDC, AJCC, and many other participating organizations.

The CAP Cancer Protocols are available on the CAP website, by clicking cap.org/CancerProtocols.





13 June 2014: Leica Microsystems announces the Leica DMi1, an entry level inverted microscope with functions specifically necessary for routine lab work. The Leica DMi1 enables cell biologists to check and document cell and tissue cultures within seconds. It is equipped with LED illumination that provides constant color temperature with up to 20 years life-time. The convenient two-hour auto-off function helps reduce energy costs. Phase contrast is available in addition to brightfield illumination.

The 40 to 50 or 80 mm working distance means that a wide variety of culture containers like flasks, dishes or multi-well plates can be used on the fixed stage. An optional object guide with different kinds of holding frames is available to securely and reliably hold and move laboratory vessels during observation and documentation.


Leica DMi1

Please click here for more information.






9 June 2014: Voicebrook, Inc. announces the release of its latest VoiceOver® module providing Structured Results Entry (SRE) for cancer reporting. VoiceOver® SRE helps pathologists comply with the College of American Pathologists (CAP) reporting guidelines for primary cancer cases.

Voicebrook has created a module fully supported by speech recognition, which imports the CAP eCC files and make them available to our customers through a user-friendly and efficient front-end interface. The VoiceOver® solution also integrates Dragon® Medical 360 speech recognition technology from Nuance Communications.

For more information on Voicebrook, please visit http://www.voicebrook.com.






5 June 2014: Ventana Medical Systems, Inc., a member of the Roche Group, announces the launch of three new companion diagnostic robust prototype assays (RPAs) for the detection of biomarkers PSMA, MDM2 and FGFR, offering biotech and pharmaceutical companies more options in exploring novel treatment options for patients with cancer. The new assays bring the company's CAP/CLIA testing menu to almost 400, nearly 100 of which are RPA assays and the remainder are IVD approved Ventana tests.

Robust prototype assays are in vitro diagnostic tests used in biomarker identification that have been validated, manufactured and used within a single clinical laboratory. The key advantage of Ventana CAP/CLIA RPAs is that they adhere to the same rigorous quality standards as the company's commercial, FDA-approved and Class I IVD assays. Biotech and pharmaceutical research development teams rely on RPAs when conducting early clinical studies to explore the potential value of specific biomarkers for a variety of indications. Data from these early research investigations can confirm, alter, or disprove a particular treatment hypothesis, saving companies valuable time and cost in bringing valuable cancer drugs to market to benefit patients..

For more information, click here.





22 May 2014: Ventana Medical Systems, Inc., a member of the Roche Group, announces the release of VENTANA Vector software, a new platform for pathology training and collaboration. The platform provides pathologists and educators with tools to build interactive training, from course development to student evaluation, and can be used to quickly and easily share scanned images with colleagues around the globe. The software enhances the learning experience, engagement and collaboration for students while providing efficiencies for educators. This innovative software is available anywhere, anytime, and is supported on a range of tablets and mobile devices.

For more information, click here.




21 May 2014: Leica Biosystems announces the launch of Aperio ePathAccess, a cloud-based software solution powered by Dell's Unified Clinical Archive (UCA) for secure pathology collaboration. Aperio ePathAccess provides direct access to sub-specialty pathologists for secondary case review, allowing 94% faster access to slides and 24/7 security through the UCA solution.

"By deploying Aperio ePathAccess, healthcare institutions can significantly lessen the time and cost of regular shipping methods for external collaboration. Studies have shown a 76% faster turn-around-time using our technology over traditional secondary case review," said Stephen White, vice president, corporate development, Leica Biosystems, Pathology Imaging.

Please click here for a short video.





9 May 2014: Leica Biosystems and Affymetrix, Inc. announce the launch of Affymetrix' fully automated RNA in situ hybridization assays ViewRNA™ eZ Assays on the Leica BOND RX staining platform. These assays detect coding RNA as well as novel non-coding markers in formalin-fixed paraffin-embedded (FFPE) tissues. Indicated for research use only*, the assays provide researchers with a powerful automated solution for drug discovery, translational research, and the development of new diagnostic tests for personalized medicine.

The Leica BOND RX system automates the staining process, bringing the benefits of consistency, reduced labor, and speed. This fully automated assay is hands-free from tissue de-waxing to counter staining and offers high sensitivity, specificity, and reproducibility with easy standardization across laboratories. ViewRNA eZ Assays represent a major technological advancement offering a robust and reliable platform to easily interrogate the function and disease relevance of any expressed genes.

For more information, click here.







28 April 2014: Primera Technology, the world's leading manufacturers of speciality printer equipment, announces its Signature Cassette Printer, designed for use in pathology and histology labs to print high-resolution text, graphics and bar codes directly onto tissue cassettes. In the past, much of this labeling has been accomplished by handwriting information with a pencil or marking pen. However, handwriting tends to be difficult to read, can be inaccurate and might even rub off during processing. The increasing use of 2D bar codes for accurate specimen identification also requires the use of a latest-generation direct-to-cassette printer. For more information, visit www.primerahealthcare.com.







24 April 2014: STEMSOFT™ Software Inc. is pleased to announce the release of a new cellular therapy laboratory software solution, STEMSOFT LAB. Designed using STEMSOFT's 20 years of experience in supplying software solutions to this community, STEMSOFT LAB provides you with a user-friendly solution to track all unique operational and manufacturing details in one location, providing a complete electronic batch process record for streamlined product and workflow management in line with regulatory and accreditation requirements. Learn more by visiting http://www.stemsoft.com/products/lab.





25 February 2014: Photodyne Technologies is pleased to offer their new line of grossing macrophotography units. The P series units are available with off the shelf Point and Shoot cameras or with top of the line DSLR cameras with 18 MP resolution allowing RAW data manipulation. These new units incorporate low DC voltage operation for enhanced safety and with all LED bulbs for cool and more efficient performance. Model 701-P is a full size console and model 702-P is a desk top model, both with 30 by 20 photographing area. Model 703-P is a smaller footprint unit with 20 by 13 photographing surface area. Prices for the new units start at $6725 for model 701-P, $5975 for model 702-P, and $5575 for model 703-P.


For more information, visit us online at www.photodyne.com, or contact us at 800-660-2147 or hrzc@earthlink.net.





21 February 2014: Mopec introduces the FD500, our Formalin Dispensing Station. Constructed of all stainless steel, it features a 7.5" W x 9" deep sink. Three grid plates are provided (one sink and two perforated). Additional standard features include: GFCI, fluorescent lighting, high low alarm lights, adjustable shelf, bi-parting lexan doors, lexan side splash shield and leveling pads.


FD500

For more information call 800-362-8491, email info@mopec.com or visit www.MOPEC.com.




\



26 August 2013: PerkinElmer and Advanced Cell Diagnostics (ACD) have entered a co-marketing agreement to develop joint applications for the visualization of multiplexed fluorescence RNA biomarkers in situ, in formalin-fixed paraffin-embedded tissues. In the past, it was not possible to detect and quantify RNA in situ in these samples due to lack of sensitivity and specificity of labels within highly autofluorescent tissues.

Click here for more information.





12 June 2013: HANSEL Stain has been the recommended in-vitro diagnostic stain for the identification of eosinophils in secretions for many years. Please see our product summary on Pathology Outlines here.

Lide Laboratories also offers other diagnostics stains including our new Urine Sediment Stain and Tinea Test Stain. Our concentrated Urine Sediment Stain combines Crystal Violet (0.1%), Ammonium Oxalate (0.03%) and Safranin O (0.25%) with the base formula used in HANSEL Stain. Our Tinea Test Stain [Lactophenol Cotton (Aniline) Blue (0.05%)] is formulated for the microscopic examination of fungi.

Please see our web page for more information: www.lidelabs.com/diagnosticstains.html. New customers can send us a request for free samples on our Contact Us web page.






14 April 2013: PSA is pleased to announce that we are now part of McKesson. This combined organization brings together an extensive portfolio of services and we are now better positioned to help our customers choose from a broader set of services from practice and revenue cycle management to coding, marketing and networking capabilities.

To learn more, visit www.McKesson.com/pathologyservices, or contact Leigh Polk at Leigh.Polk@McKesson.com.





13 October 2012: Introducing EXAKT’s NEW Pathology Saw. Designed specifically for pathology lab use, this bone saw offers the SAFEST alternative for grossing samples. Unlike butcher saws used in many labs, the diamond band of the EXAKT saw does not cut, but grinds the bone very precisely. There is no immediate risk of injury to the technician if the band is touched unintentionally. The EXAKT 312 Diamond Pathology Saw easily cuts metal implants or screws encountered during the grossing process, without destroying the sample. Even very small specimens can be cut safely and precisely! Visit www.exaktusa.com/pathology-saw and watch the EXAKT Pathology Saw Video.







11 November 2011: bioTheranostics, Inc., a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, announces a clinical study that links CancerTYPE ID® molecular testing with improved patient outcome. Patients in which CancerTYPE ID predicted a colorectal site of origin that subsequently received site-specific therapy had a median survival three times that of what has been reported in patients treated empirically for cancer of unknown primary (CUP). These results make CancerTYPE ID the only marketed molecular cancer classifier to demonstrate therapeutic response and patient benefit based on molecular tumor profiling.

The study, led by John Hainsworth, MD, of the Sarah Canon Research Institute, A Retrospective Study of Treatment Outcomes in Patients with Carcinoma of Unknown Primary Site and a Colorectal Cancer Molecular Profile (Clin Colorectal Cancer 2011 Oct 13 [Epub ahead of print]), focused on the improved treatment response and survival in a group of patients in which CancerTYPE ID results were utilized in the selection of site-specific therapy. According to the study findings, which will be published in the December issue of Clinical Colorectal Cancer and currently are available online, 75 percent of the patients showed negative colonoscopy results, and approximately half the patients had atypical immunohistochemistry for colorectal cancer. Significantly, CancerTYPE ID was used as part of the routine work-up and site-specific treatment was selected based on the molecular assay prediction.

The study results demonstrated a 50 percent response rate in patients treated with first-line regimens for colorectal cancer versus only 17 percent in patients treated with current empiric therapies for CUP (P value = 0.0257). Patients predicted to have colorectal cancer by CancerTYPE ID and treated with colorectal cancer treatment regimens experienced a median survival of 27 months. In comparison, patients treated with empiric CUP treatment have historical median survivals ranging from 8 to 11 months.

For more information please contact Wendy Johnson, Associate Director Marketing, bioTheranostics, 858-587-5887 or click here.






26 July 2011: OPTRONICS presents a case study about High Definition Hematology. In 2009, the Royal Berkshire Hospital (RBH) made the decision to update its microscope camera system. Located in the Haematology Department, the equipment originally consisted of a microscope mounted analogue video camera connected to a 21-inch professional monitor. This was used for presentations and training purposes for over ten years until it started to fail and display picture defects. Click here to read the short article.

For more information, contact Rich Crandall, Director of Business Development at 805.562.3980 or rcrandall@optronics.com, or visit us online at http://www.optronics.com.






26 January 2011: ARUP’s Online Scientific Resource for Research and Education provides more than 20 free CME courses for physicians. Course topics reflect current issues and developments in pathology; new courses are added monthly. This resource is provided by ARUP’s medical directors, who are faculty at the University of Utah School of Medicine, along with other highly qualified expert contributors.

The University of Utah School of Medicine designates these educational activities for AMA PRA Category 1 credit(s) and affirms that they meet the criteria for Self-Assessment Modules (SAM) credit to apply toward the Maintenance of Certification (MOC) by the American Board of Pathology.

For more information, click here.


 

 

 

10 February 2009:  Vachette Pathology is proud to announce its newly improved website Vachettepathology.com. The website will have more content and more information. The goal of the website will be to concentrate all the knowledge and experience we have into a single database that is more useable for both our current and potential customers.

 

Vachette Pathology is a practice management firm that specializes in pathology. Currently we work with over 450 pathologists nationwide and are commonly held as the industry leaders in the business of pathology and laboratory management.

 

If you have any questions or for further information, please contact Mick Raich toll free at 866-407-0763, or email mraich@vachettepathology.com




End of New Products and Services page



Advertisement